2023
The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsEstrogen Receptor alphaFemaleHumansReceptors, EstrogenReceptors, ProgesteroneConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2017
Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.
Wright N, Rida P, Krishnamurti U, Li X, Aneja R. Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity. Frontiers In Bioscience-Landmark 2017, 22: 193-211. PMID: 27814611, DOI: 10.2741/4481.Peer-Reviewed Original ResearchConceptsEthnic disparitiesAfrican AmericansAggressive breast cancer subtypeUnique tumor biologyBreast cancer subtypesPrecision medicine toolsDiagnostic assaysIndividualized cancer treatmentRacial health disparitiesClinical outcomesDevelopment of drugsPatient populationAncestry-associated differencesEfficacy biomarkersTargeted drugsHigh recurrenceMortality rateCentrosomal aberrationsBreast tumorsTumor biologyCancer subtypesHealth disparitiesMedicine toolsCancer treatmentPersonalized oncology